Chronic Pain in Youth and Substance Misuse, Mental Illness, and Long-Term Prescription Opioid Use in Adulthood: A Retrospective Longitudinal Cohort Study

Andrew Lambarth,Chengsheng Ju,Alasdair Warwick,Rohan Takhar,Caroline Dale,Andrew Morris,Debajit Sen,Li Wei,Reecha Sofat
DOI: https://doi.org/10.2139/ssrn.4083742
2022-01-01
SSRN Electronic Journal
Abstract:Background: Epidemiological studies indicate a prevalence of chronic and recurrent pain in children of 15-30%, with 8% of children reported as having severe and frequent pain. The long-term implications of chronic pain (CP) in childhood are uncertain. Using electronic health records (EHRs) we used both disease codes and medicines prescription records to investigate the scale of CP in children and young people (CYP), and if CP and/or use of analgesic medicines at an early age is associated with substance misuse (SM), use of prescription opioids, and poor mental health (MH) in adulthood.Methods: We conducted a cohort study using The Health Improvement Network (THIN) database. We identified individuals with CP aged 2-24. Exposure was either by diagnostic code (diagnosis-exposed), inferred by repeat prescription of medicines commonly used to treat pain (prescription-exposed), or both. Follow-up began at 25, and the unexposed population acted as comparators. We calculated hazard ratios (HR) for MH and SM outcomes, and rate ratios (RR) for opioid prescriptions in adulthood. Additionally, we investigated which diagnoses, if any, were over-represented in the prescription-exposed subgroup.Findings: The cohort constituted 853,625 individuals; 146,431 were exposed to CP (diagnosis-exposed=115,101, prescription-exposed=20,298, both-exposed=11,032), leaving 707,194 as comparators. Median age at index exposure was 18·7 years (IQR 14·7-22·3). Adjusted HRs (95%CI) were significantly greater among the pooled exposed group for MH (HR 1·31 [1·29-1·33]) and SM (HR 1·17 [1·12-1·23]) outcomes. The RR for opioid prescriptions was also greater within the exposed-group (2·88 [95%CI 2·74-3·03]). Outcomes varied between exposure subgroups, with prescription- and both-exposure tending to have higher HRs for adverse outcomes.Interpretation: CP in CYP is associated with increased prescription opioid use, and adverse MH and SM outcomes in adulthood. Both pain and medicines used to treat it may be implicated in life-long harms. Early recognition of CP in CYP and utilising non-pharmacological management options may help minimise overprescribing, and long-term reliance on dependence-forming-drugs.Funding Information: No funding was provided specifically for this work. AL is supported by UCLH Charity (via grant number MR/W002566/1). CD is supported by Health Data Research UK. AW is supported by the Wellcome Trust.Declaration of Interests: The authors have no conflicts of interest to declare.Ethics Approval Statement: Our protocol received approval from an independent Scientific Review Committee (reference number 20SRC074), and the NHS Health Research Authority Research Ethics Committee was informed.
What problem does this paper attempt to address?